Altesa BioSciences Presents Positive Phase 2 Challenge Study Results for Vapendavir at American Thoracic Society International Conference 2026

Randomized, placebo-controlled challenge study demonstrated reduced viral load, reduced inflammation, maintained lung function and improved patient-reported outcomes in COPD patients treated with vapendavir following rhinovirus infection Phase 2B CARDINAL study, which recently enrolled...